PATENT CLAIM ANALYSIS

Application Number: 16127509
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "021900"]

Abstract:
The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.

Claim (Index 5):
A combination according to  claim 1 , wherein the FXR agonist is 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3 carboxamido)methyl)benzoic acid, a pharmaceutically acceptable salt, prodrug and/or ester thereof and/or an amino acid conjugate thereof, e.g. meglumine salt.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.12121
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16335662', '15612124', '15263033', '15598734', '15551224']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7666559921012148
- 35 USC 102 Novelty (BERT): 0.5138297901567925
- Combined Prediction Score: 0.7413733719067725
- Mean Citation Score: 232.16857200000004
- Max Citation Score: 309.541
- Similarity Product: 261.9341812963486

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test